Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

NCT ID: NCT04870762

Last Updated: 2025-10-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

119 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-26

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients' teeth and gums during radiation therapy. A customized, 3D-printed oral stent may help to reduce mouth blisters and/or sores that may develop in patients while receiving head and neck radiation therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To evaluate the acute mucositis rates in non-target mucosa of patients who receive head and neck radiation with or without a customized 3D printed oral stent.

SECONDARY OBJECTIVES:

I. To record patient reported outcomes during radiotherapy. II. To evaluate patient narcotic use during radiotherapy. III. To evaluate the imaging and dosimetric differences in head and neck radiotherapy with and without a customized 3D printed oral stent.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients wear 3D printed oral stent during standard of care radiotherapy.

ARM II: Patients receive standard of care during treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Carcinoma Malignant Parotid Gland Neoplasm Maxillary Sinus Carcinoma Nasal Cavity Carcinoma Oral Cavity Carcinoma Tongue Carcinoma Tonsillar Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (3D printed oral stent)

Patients wear 3D printed oral stent during standard of care radiotherapy.

Group Type EXPERIMENTAL

Best Practice

Intervention Type OTHER

Receive standard of care

Medical Device Usage and Evaluation

Intervention Type OTHER

Wear 3D printed oral stent

Arm II (standard of care)

Patients receive standard of care during treatment.

Group Type ACTIVE_COMPARATOR

Best Practice

Intervention Type OTHER

Receive standard of care

Medical Device Usage and Evaluation

Intervention Type OTHER

Wear 3D printed oral stent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Best Practice

Receive standard of care

Intervention Type OTHER

Medical Device Usage and Evaluation

Wear 3D printed oral stent

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

standard of care standard therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is dispositioned to receive 5-7 weeks of definitive or adjuvant radiotherapy for treatment of a diagnosed head and neck malignancy
* Age 18 or older
* ECOG PS 0-2
* The participant will receive either (a) radiation alone or (b) radiation with concurrent chemotherapy of any kind(s)
* Signed study-specific consent form

Exclusion Criteria

* Prior head and neck radiotherapy
* Participants is unable to fit a tongue-lateralizing or tongue-depressing stent
* Severe trismus with an incisal opening of \<10 mm
* Inability to comply with the study procedures
* Participants younger than 18 years of age
* Participants must not be pregnant
* Cognitively impaired subjects
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Lee

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner Health/Banner Research

Phoenix, Arizona, United States

Site Status RECRUITING

Baptist MD Anderson Cancer Center

Jacksonville, Florida, United States

Site Status RECRUITING

Community MD Anderson Cancer Center East

Indianapolis, Indiana, United States

Site Status RECRUITING

Community MD Anderson Cancer Center South

Indianapolis, Indiana, United States

Site Status RECRUITING

Community MD Anderson Cancer Center North

Indianapolis, Indiana, United States

Site Status RECRUITING

Cooper Hospital University Medical Center

Camden, New Jersey, United States

Site Status RECRUITING

M D Anderson Cancer Center

Houston, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anna Lee, MD

Role: CONTACT

932-750-1920

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gary V. Walker, MD

Role: primary

480-256-6444

Mark E. Augspurger, MD

Role: primary

904-202-7300

Aleander Augustyn, MD

Role: primary

Alexander Augustyn, MD

Role: primary

Alexander Augustyn, MD

Role: primary

Megan Mezera, MD

Role: primary

856-735-6109

Ann Lee, MD

Role: primary

932-750-1920

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

M D Anderson Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2021-03221

Identifier Type: REGISTRY

Identifier Source: secondary_id

2020-1153

Identifier Type: OTHER

Identifier Source: secondary_id

2020-1153

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intensive Preventative Dental Program Pilot Study
NCT07218068 COMPLETED EARLY_PHASE1